Atlas Venture is a leading biotech venture capital firm. With the goal of doing well by doing good, we have been building breakthrough biotech startups since 1993. We work side by side with exceptional scientists and entrepreneurs to translate high impact science into medicines for patients. Our seed-led venture creation strategy rigorously selects and focuses investment on the most compelling opportunities to build scalable businesses and realize value.?
Atlas Venture的外部链接
300 Technology Square
US，MA，Cambridge，02139
An exciting day at TRIANA Biomedicines as they announce their research collaboration with Pfizer. TRIANA is focused on building a target-first molecular glue discovery pipeline for difficult to address disease targets. Congratulations to the teams!
Big news today for TRIANA! Announcing a research collaboration with Pfizer to Discover?novel molecular glue degraders https://lnkd.in/exAGkn68
Join us and other host firms F-Prime Capital, 5AM Ventures, Osage University Partners (OUP), and RA Capital Management, for the 2025 #Science2Startup symposium! This year's event is set for Wednesday, May 14th, featuring top scientists presenting to an audience of leading #biotech and #pharma executives, VCs, and entrepreneurs. Have a groundbreaking idea for a biotech #startup? Submit your application by Friday, November 15th: https://lnkd.in/e7bPwMzX
Congratulations to the Judo team on their launch today! It has been a privilege to build Judo alongside Atlas and TCG over the past three years, and I’m especially grateful for the support from Kevin Bitterman and Jeff Goater. The journey from concept to a well-tuned engine on its way to the clinic, with a stellar team and strong financing, hasn’t always been easy—but seeing all the pieces come together now is incredibly exciting. This is just the beginning and the future looks bright with Rajiv Patni and Alfica Sehgal leading the way! https://judo.bio/ https://lnkd.in/ep9xqFP7
Wonderful to see Allison August, M.D., Chief Medical Officer at Comanche Biopharma recognized on this impressive list! Congratulations!
Congratulations to our Chief Medical Officer Allison August, M.D. for being featured by Endpoints News in its Women in Biopharma 2024 Special Report, which highlights 20 women who are breaking new ground in #biopharma R&D. Our mission at Comanche is to develop and make globally available the first treatment targeting a root cause of preeclampsia. As CMO, Allison is overseeing the clinical development of CBP-4888, our investigational #siRNA therapy that targets an underlying cause of preeclampsia, overproduction of the protein sFlt1 in the placenta. Allison brings a unique blend of maternal health expertise as an obstetrician-gynecologist, robust clinical development experience, profound intellect, inspiring leadership, incredible grit, and unwavering compassion for patients.?We are so honored to work with her every day! Read more about Allison and the other trailblazing women in biopharma R&D featured in this year's report: https://bit.ly/3BBC7dA #MaternalHealth #preeclampsia
A wonderful start to the week for Judo Bio as they officially launch with $100M in funding! Judo has discovered a novel approach to create oligonucleotide medicines targeted to the kidney, an organ that has been challenging to access for genetic medicines.?Congrats to the Judo team! #doingwellbydoinggood
A big day for Triveni Bio as they announce their $115 Million Series B to support pipeline expansion of therapeutics targeting immunological and inflammatory disorders. So excited to be a part of their growth and impact. Congrats to the team!
We are thrilled to be a part of the $400 Million Series A financing and official launch of Kailera Therapeutics! This clinical-stage biopharmaceutical company is focused on advancing a broad pipeline of next-generation therapies for the treatment of obesity and related conditions. They are developing several clinical-stage injectable and oral therapies that demonstrated potential as best-in-class treatments for chronic weight management. A huge congrats to the team and all involved!
Huge congratulations to the Lifordi Immunotherapeutics, Inc. team and on being recognized by Endpoints News as Winner of Endpoints 11 Award! Lifordi Immunotherapeutics, Inc. is developing antibody-drug conjugates (ADCs) for the treatment of autoimmune and inflammatory disorders.
Attention #biotech entrepreneurs and researchers! Don’t miss your chance to pitch your #startup ideas at #Science2Startup 2025 to top biotech and #pharma executives, VCs, and entrepreneurs in the Boston area. Applications are due Friday, November 15th: https://lnkd.in/e7bPwMzX
It's a ride like no other - check out our Associate/Senior Associate need on our Investment Team. We don't teach venture creation, we do venture creation. https://lnkd.in/ecPFbD24